NMDAR antagonists for the treatment of diseases associated with angiogenesis

Abstract

The present invention relates to an N-Methyl-D-aspartate (NMDA) receptor antagonist, for use in the treatment of diseases associated with angiogenesis such as tumor angiogenesis, ocular neovascular disease, Age-related macular degeneration (AMD).

Claims

1. A method of inhibiting angiogenesis in a subject in need thereof comprising administering to the subject an antagonist of N-Methyl-D-aspartate receptor (NMDAR) or an inhibitor of NMDAR expression.

2. The method of claim 1, wherein the antagonist of NMDAR is selected from the group consisting of: i. a small organic molecule; ii. an anti-NMDAR antibody or antibody fragment; and iii. a polypeptide.

3. The method of claim 1, wherein the inhibitor of NMDAR expression is a siRNA, a ribozyme, or an antisense oligonucleotide.

4. A method of treating tumor angiogenesis in a subject in need thereof comprising administering to the subject an antagonist of N-Methyl-D-aspartate receptor (NMDAR) or an inhibitor of NMDAR expression, wherein the antagonist or the inhibitor inhibit angiogenesis.

5. The method of claim 4, wherein the antagonist of NMDAR is selected from the group consisting of: i. a small organic molecule; ii. an anti-NMDAR antibody or antibody fragment; and iii. a polypeptide.

6. The method of claim 4, wherein said inhibitor of NMDAR expression is a siRNA, a ribozyme, or an antisense oligonucleotide.

7. The method of claim 4, wherein the antagonist of NMDAR is selected from the group consisting of: i. a small organic molecule; ii. an anti-NMDAR antibody or antibody fragment; and iii. a polypeptide.

8. The method of claim 4, wherein the inhibitor of NMDAR expression is a siRNA, a ribozyme, or an antisense oligonucleotide.

Description

FIGURES

(1) FIG. 1: Activation of endothelial cell NMDAR contributes to vascular remodeling in the development of pulmonary hypertension. (a) The table summarizes quantitation of total membrane GluN1 i.e NMDAR available for activation, in endothelial cells and also specifically in synaptic-like contact (defined as a close contact <70 m between two endothelial cells without junctions). A concentration index of GluN1 in the synaptic-like contacts was determined calculating the ratio of the percent of membrane GluN1 in these synaptic-like contacts divided by the percent of synaptic contact length. (b) Quantitative RT-PCR analysis of GRIN1 gene expression from total RNA of CD31+ cells and CD31 cells isolated from the lungs of wild-type mice (n=4) and knocked-out mice (n=4) for the NMDAR in ECs showing efficiency of Grin1 knockout in ECs. Grin1 gene expression is normalized to Actinb gene expression. Values are normalized to those of WT mice. (c) Right Ventricular Systolic Pressure (RVSP) measurement in wild-type (n=11-12) and knocked-out mice for the NMDAR in ECs (n=17-18) after 3 weeks of normoxia or chronic hypoxia (FiO.sub.2: 10%). (d) Ratio of right ventricular weight to left ventricular plus septum weight (Fulton index) measured in wild-type (n=12) or knocked-out mice for the NMDAR in ECs (n=19-20) after 3 weeks of normoxia or chronic hypoxia (FiO.sub.2: 10%). Same experiment as in c). (e) Morphometric analysis of pulmonary vessels in wild-type or knocked-out mice for the NMDAR in ECs after 3 weeks of normoxia or chronic hypoxia (FiO.sub.2: 10%). Same experiment as in c) and d). Pulmonary vessels are divided in 4 groups depending on the external vessel diameter (less than 30 m, from 30 m to 50 m, from 50 m to 75 m and from 75 m to 125 m). 100 vessels were analyzed for each group (20 vessels per group and per mice). Each vessel was classified as a non muscularized vessel (VWF+, -smooth muscle actin-), partially muscularized vessel (VWF+, -smooth muscle actin+/), and fully muscularized vessel (VWF+, -smooth muscle actin+). (f) Measurement of control hPMVEC proliferation (BrdU incorporation), after exposure to VEGF-A (10 ng.Math.m.sup.1) in absence or presence of incremental concentrations of NMDAR antagonists MK-801 or memantine (MMT) (both from 10 M to 100 M). Values are normalized to those of non-stimulated cultures. Data are means of eight replicates and the graphs are representative of three independent experiments. (g) In vitro angiogenesis experiments using control hPMVEC in the Matrigel assay with or without 100 M NMDAR antagonist (+)-MK-801 maleate. On the left automatic quantification of total tube length and total number of nodes using the Angiogenesis analyzer plugin from ImageJ software on a total of 7-8 images (1 image/replicate, each image covering nearly all the well area). Values are expressed as percent of control. On the right representative transmitted light microscopy images (upper and middle images) and associated skeletonized images (lower images) of three experiments are shown. Scale bar 500 m. Similar results were obtained using 50 M DAP-V (FIG. 2f). (h) In vitro angiogenesis experiments in a coculture assay using control hPASMC and hPMVEC. hPMVEC were seeded on the top of the confluent hPASMC layer with or without incremental concentrations of NMDAR antagonist (+)-MK-801 maleate ranging from 10 to 100 M, in six replicate cultures for each concentration. CD31 labelling was used to visualize the tube network after 15 days of co-culture.
Statistical significance was determined by Mann Whitney test (b), regular two-way ANOVA followed by Bonferonni's test (c-e), one-way ANOVA followed by Bonferonni's multiple comparison test (f, h) or Student's t test (g). *p<0.05, ***p<0.001 compared to WT/control (b-e, g, h) or .sup. p<0.001 compared to control, *p<0.05, ***p<0.001 compared to VEGF (f). Values are medianinterquartile range (b) or meanSEM (c-h).

(2) FIG. 2: Supplementary figures about activation of endothelial cell NMDAR contributes to vascular remodeling in the development of pulmonary hypertension. (a) Quantitation of total GluN1-associated immunogold particles per 100 m.sup.2 of endothelial cells in arteries from a control patient, and in an intimal lesion and plexiform lesion from a PAH patient. (b) Genotyping of Tek-creXGrin1 mice. For the Cre gene, the first agarose gel shows a band at the expected molecular weight: lane 1 is the DNA ladder, lane 2 is a WT mice (absence of band) and lane 3 is a recombinant mice (presence of a band at 390 bp). For the floxed Grin1 gene, the second agarose gel shows bands at expected molecular weights: lane 4 is the DNA ladder, lane 5 is a hemizygous mice (two bands at 180 bp and 280 bp), lane 6 is a homozygous mice (floxed Grin1 band only, at 280 bp) and lane 7 is a WT mice (WT Grin1 band only, at 180 bp). (c) Age of wild-type (n=12) and knocked-out mice for NMDAR in ECs (n=19-20) after 3 weeks of normoxia or chronic hypoxia, that were used in the experiment depicted in FIG. 1c-e. (d) Body weight of wild-type (n=12) and knocked-out mice for NMDAR in ECs (n=19-20) after 3 weeks of normoxia or chronic hypoxia that were used in the experiment depicted in FIG. 1c-e. (e) Measurement of control hPMVEC proliferation (BrdU incorporation) after exposure to fetal bovine serum (FBS 10%) in absence or presence of NMDAR antagonists MK-801 or memantine (MMT) (both from 10 M to 100 M). Values are normalized to those of non-stimulated cultures. Data are means of six replicates and the graph is representative of three independent experiments. (f) In vitro angiogenesis experiments using control hPMVEC in the Matrigel assay with or without 50 M NMDAR antagonist DAP-V. Automatic quantification of total tube length and total number of nodes using the Angiogenesis analyzer plugin from ImageJ software on a total 7-8 images (1 image/replicate, each image covering nearly all the well area). Values are expressed as percent of control. Data are representative of two independent experiments. (g) In vitro angiogenesis experiments in a coculture assay using control hPASMC and hPMVEC with or without incremental concentrations of NMDAR antagonist (+)-MK-801 maleate ranging from 10 to 100 M, in six replicate cultures for each concentration. Different quantification method of the same experiment as in FIG. 1h. Automatic quantification of total tube length represented by CD31 staining area performed using AngioQuant software. Values are expressed as percent of control. Statistical significance was determined by Kruskal Wallis test followed by Dunn's multiple comparison tests (a), regular two-way ANOVA followed by Bonferonni's test (c, d), one-way ANOVA followed by Bonferonni's multiple comparison test (e, g) or Student's t test (f). *p<0.05, **p<0.01, ***p<0.001 compared to WT/control (a, c, d, f, g) or .sup. p<0.01, .sup. p<0.001 compared to control, *p<0.05, ***p<0.001 compared to FBS 10% (e). Values are medianinterquartile range (a) or meanSEM (c-d, f-h).

EXAMPLE

(3) Material & Methods

(4) Cell Culture

(5) Experiments requiring cells were performed on human pulmonary arterial smooth muscle cells (hPASMC, LONZA, Basel, Switzerland), human pulmonary microvascular endothelial cells (hPMVEC, LONZA, Basel, Switzerland), between P4 and P7, both from healthy non-smoker and non-alcoholic donors and on primary culture of hippocampal neurons from rat fetuses.

(6) For hPASMC culture, 250 000 cells were seeded in T75 flasks (BD Falcon, CORNING, Tewksbury, Mass., USA) and grown in the SmGm2 complete medium containing SmBm basal medium and also basic fibroblast growth factor, epidermal growth factor, insulin and gentamycin/amphotericin 1 (all from LONZA, Basel, Switzerland).

(7) For hPMVEC culture, 375 000 cells were seeded in T75 flasks (BD Falcon, CORNING, Tewksbury, Mass., USA) and grown in the EGM2-MV complete medium containing EBM2 basal medium and basic fibroblast growth factor-b, epidermal growth factor, vascular endothelial growth factor, hydrocortisone, ascorbic acid, insulin-like growth factor and gentamycin/amphotericin 1 (all from LONZA, Basel, Switzerland).

(8) All cells were cultured at 37 C. in a humidified atmosphere of 5% CO.sub.2 and 95% air.

(9) Angiogenesis Assays

(10) Matrigel assays were performed on -slide angiogenesis (IBIDI, Martinsried, Germany). 100 L of phenol-red free matrigel matrix (BD, Franklin lakes, N.J., USA) were put in each wells and slides were incubated during 30 min at 37 C. Then, 50 L of EGM2-MV medium with our without NMDAR antagonists (100 M (+)-MK-801 maleate or 50 M DAP-V, both from ABCAM BIOCHEMICALS, Cambridge, UK) were added on matrigel gels during 1 hour. 3500 hPMVEC were seeded in each well in presence or absence of NMDAR antagonists. After 4 hours, bright-field images of capillary-like structures were captured using Eclipse 80i microscope coupled to Nis Elements BR2.30 software. Images were then automatically analyzed with Angiogenesis analyzer plugin for ImageJ software resulting in total tube length and total number of nodes determination.

(11) For the hPASMC/hPMVEC co-culture model of angiogenesis, 20000 PASMC were seeded on glass coverslips in a 12-well plate (CORNING, Tewksbury, Mass., USA) and cultured until confluence in SmGm2 complete medium. After reaching high confluence, 80000 PMVEC were seeded on the top of the PASMC layer switching the medium from SmGm2 complete medium to a modified EGM2-MV complete medium containing 2% FBS with our without NMDAR antagonist MK-801 at 0 M, 10 M, 30 M or 100 M MK-801 (6 replicates per condition). Medium was changed every 2 to 3 days and after 15 days of co-culture, cells were fixed and CD31 was stained. After staining, 55 images of each coverslip were captured using mosaic mode of acquisition with a Zeiss Axio Observer Z1 microscope coupled to Axiovision 4.8 software (both from CARL ZEISS, Oberkochen, Germany). Images were analysed using ImageJ software in order to calculate the CD31 staining area to the total cell area ratio. This ratio was further named as the total tube length. Automatic quantitation was also achieved using AngioQuant software.sup.70 to determine total tube length.

(12) Animal Models

(13) All animals were used in strict accordance to the European Union regulations (Directive 2010/63/UE) for animal experiments and complied with our institution's guidelines for animal care and handling. All animals were maintained in a temperature and humidity-controlled room with a 12 h/12 h light/dark cycle with access to a standard rat chow and water ad libitum. Following procedures performed on rats or mice, were approved by the ethical committee CEEA26 (Animal experimentation ethic committee no 26) and the French ministry of higher education and research.

(14) The transgenic mice strain used are B6.129S4-Grin1.sup.tm2Stl/J (further named as GRIN1.sup.fl/fl mice), (from JACKSON LABORATORY, Bar Harbor, Me., USA) and B6.Cg-Tg(Tek-cre/ERT2)1Arnd/ArndCnrm (further named as Tek-cre mice) (EUROPEAN MOUSE MUTANT ARCHIVE, CNR Monterotondo, Monterotondo, RM, Italy). Briefly, GRIN1.sup.fl/fl mice were crossed with Tek-cre mice. For NMDAR knocked out in endothelial cells, experiments were performed on male Tek-creGRIN1.sup.fl/fl mice and male Tek-cre mice were used as controls after 5 weeks of Tamoxifen-containing chow (HARLAN LABORATORIES, Indianapolis, Ind., USA) administration followed by 1 week of standard chow. Pulmonary hypertension was induced exposing mice to 3 weeks of hypoxia (10% FiO.sub.2). Then, mice were submitted to anesthesia induced by inhalation of isoflurane 3% mixed with air and maintained decreasing isoflurance concentration between 1% and 1.5%. Right-heart catheterization and organ processing were performed using standard methods. The heart was taken out the 30 thoracic cage, auricles were removed and right ventricles were separated from left ventricles associated to septa. The weight of each part was measured and the ratio of the right ventricle weigh to the left ventricle with septum weigh was calculated for each mouse. Lungs were processed inflating them with 10 mL of a mixture of saline and OCT 1/1 ratio (Shandon Cryomatrix, THERMOFISCHER SCIENTIFIC). Ventricles and inflated lungs were then frozen in cooled isopentane (VWR) and stored at 80 C.

(15) For morphometric analysis of pulmonary arteries, 6 m thick sections of mouse lungs were cut with a cryomicrotome (LEICA MICROSYSTEMS). Sections were allowed to dry during 1 hour under a hood. Then, they were fixed in cold acetone for 10 minutes. 10% goat serum plus 5% mouse serum were incubated for 1 hour to prevent unspecific binding of antibodies. Anti-VWF and 10 Anti-alpha smooth muscle cell-FITC antibodies were incubated in presence of 2% mouse serum during 1 hour at room temperature. A negative control was performed omitting primary antibodies. The secondary antibody was incubated during 30 minutes in presence of 2% mouse serum. DAPI (LIFE TECHNOLOGIES) diluted at 1/500 was incubated during 1 minute. Glass slides were finally mounted using Dako Fluorescent mounting 15 medium (DAKO). Sections were then analyzed using Eclipse 80i microscope coupled to Nis Elements BR2.30 software (NIKON). For statistical analysis performed on mouse lungs, intrapulmonary arterioles were divided in four groups based on their external diameter: less than 30 m, from 30 m to 50 m, from 50 m to 75 m and from 75 m to 125 m. 20 arterioles per 20 category identified with the VWF staining were qualified as non muscularized, partially muscularized or fully muscularized based on the alpha smooth muscle actin staining. 5 mice/group were included in the study.

(16) Results

(17) Activation of Smooth Muscle Cell NMDAR Contributes to the Vascular Remodeling Occurring During PH Development.

(18) NMDAR activation has been previously associated to aortic smooth muscle cell proliferation depending of MAPK and PI3K signaling pathway activation.sup.25. Besides, NMDAR activation has been pointed out as an important component of the aberrant proliferation of cancer cells and PAH PASMCs exhibit a cancer-like phenotype. To determine a potential role of PASMC NMDAR in progressive vascular remodeling and subsequent PAH, we have developed knockout (KO) mice for NMDAR, with targeted deletion of the Grin1 gene in SMCs using a Cre/Lox approach. Grin1 gene expression was clearly reduced in pulmonary arteries from KO mice compared to wild-type (WT) mice indicating efficient genetic recombination. Age-matched KO and WT male mice were exposed to 3 weeks normoxia or hypoxia (FiO.sub.2 10%) in order to induce experimental PH. Normoxic KO and WT mice didn't show any differences in right ventricular systolic pressure (RVSP) and right cardiac hypertrophy (Fulton index) opposite to hypoxic KO mice presenting significantly lower RVSP and Fulton index than hypoxic WT mice. This was associated to a decreased muscularization of small pulmonary arterioles (<50 m external diameter) in hypoxic KO mice compared to WT mice. Interestingly, a decreased muscularization of large arteries (from 75 m to 125 m external diameter) was also noticed in KO mice compared to WT mice independently of hypoxia exposure, suggesting a role for NMDAR in physiological smooth muscle cell coverage of pulmonary arteries. No significant difference in body weight was noticed between KO and WT mice in both normoxia and hypoxia. As proliferation of hPASMCs is a crucial determinant of vascular remodeling associated to increased pulmonary vascular resistance and pressure, we analyzed the role of NMDAR activation in hPASMCs proliferation. Using two non-structurally related NMDAR uncompetitive antagonists, MK-801 and memantine (MMT), we show dose-dependent inhibition of proliferation induced by PDGF-BB, a growth factor of PASMCs, overexpressed in PAH thus overactivating the PDGFR and participating to vascular remodeling.sup.37. Interestingly, a crosstalk of NMDAR and PDGFR pathways is operating in neurons of the CNS, with PDGF stimulation modulating NMDAR activity and orientating NMDAR response to activation of proliferation-related MAPK and CREB signaling pathways.sup.38,39. Importantly, NMDAR antagonists MK-801 and MMT attenuated hPASMCs proliferation induced by PDGF-BB without adding any NMDAR agonists to the medium. Contrary to ET-1 stimulation, PDGF-BB did not further increase the basal release of glutamate from control hPASMCs suggesting a role in mobilizing NMDARs. Thus, we explored the potential of PDGF-BB to phosphorylate GluN1 in hPASMCs on Ser896, a site phosphorylated in pulmonary arteries of PAH patients. Kinetics analysis showed increased GluN1 phosphorylation after 10 min of PDGF-BB exposure and followed by a slight decrease after 30 min to 1 h. These results indicate that PDGF-BB could activate NMDAR trafficking, phosphorylating the obligatory GluN1 subunit within minutes, then contributing to proliferative effects. Thus, PDGF-BB and/or ET-1 could be responsible for the increased phosphorylation of GluN1 observed in situ in pulmonary arteries from PAH patients especially in PASMC, a cell type known to express abundantly the PDGFR. We conclude that NMDAR expressed by PASMC contributes to vascular remodeling, resulting in an increased RVSP and subsequently right cardiac hypertrophy in the hypoxic mice model. Moreover, PDGF-BB could mobilize NMDAR in order to participate to the resulting proliferative effect.

(19) Activation of Endothelial NMDARs Contributes to the Vascular Remodeling Occurring During PH Development.

(20) It has been suggested that NMDAR activation in CNS endothelial cell can disturb the endothelial barrier through production of reactive oxygen species, favor monocyte transmigration and induce proliferation.sup.18-20,22. As vascular remodeling associated to PAH involves breakdown of endothelial junctions, oxidant stress, proliferation and adventitial inflammation.sup.40, we evaluated the participation of endothelial NMDARs in PAH development. Correlative light and electron microscopy, allowed investigating the number and the localization of NMDARs (precisely GluN1 protein) in pulmonary artery endothelial cells from a PH patient compared to control. We focused on an intimal and a plexiform lesion as they mainly depend on the endothelial layer dysfunction. Synaptic-like contact was defined as a close contact <70 m between two endothelial cells without junctions. We show that the total number of immunogold particles per 100 m.sup.2 of endothelial cells (FIG. 2a), the partition/distribution between membrane and cytoplasmic GluN1 as well as the proportion of synaptic-like contact length relative to the total membrane length (FIG. 1a) did not change between the PAH artery compared to control artery. Importantly, membrane GluN1 located in these contact areas is increased in plexiform lesion compared to intimal lesion and control artery (29.5% of total membrane GluN1 in plexiform lesion vs 7.7% in intimal lesion and 4.1% in control artery). In the intimal lesion, membrane GluN1 proteins are 3.5 fold enriched inside/along synaptic-like contacts compared to the control artery. In plexiform lesion, this index even reaches 7.1 (FIG. 1a). These membrane-GluN1 proteins represent available NMDAR for activation that seems accumulated and/or concentrated inside/along synaptic-like contact between endothelial cells suggesting increased glutamatergic signaling between endothelial cells in PAH lesions. To explore the potential involvement of endothelial NMDAR in the vascular remodeling associated to PH we developed endothelial cell-targeted KO mice for Grin1 gene using tamoxifen-inducible Cre/Lox strategy. After tamoxifen administration, Grin1 gene expression was markedly reduced in CD31+ cells isolated from the lung of KO mice compared to WT mice suggesting efficient Grin1 gene recombination (FIG. 1b). These mice were exposed to normoxia or hypoxia for 3 weeks before measuring RVSP and calculating the Fulton index. No difference was observed in body weight although normoxic KO mice were slightly older than WT mice. In normoxic mice, no difference in RVSP or Fulton index between WT and KO mice was highlighted. After hypoxia, KO mice presented a decreased right cardiac hypertrophy and a decreased RVSP (FIG. 1c,d). Morphometric analysis of the pulmonary arteries revealed a significant decrease of the muscularization only in small arterioles (<50 m external diameter) between WT and KO mice after chronic hypoxia (FIG. 1e). No difference was observed for larger arteries between WT and KO mice in both normoxia and hypoxia. As excessive endothelial cell proliferation and dysregulated angiogenesis are part of the vascular remodeling processes demonstrated in PAH plexiform lesions.sup.41, and because VEGF signaling and NMDAR have been shown to cooperate in neurons in the CNS.sup.42, we have investigated whether NMDAR activation could participate to endothelial cell proliferation and angiogenesis. NMDAR antagonists MK-801 and MMT dose-dependently inhibit hPMVEC proliferation stimulated either by FBS 10% or VEGF-A 10 ng.Math.ml.sup.1 without adding exogenous NMDAR agonists (FIG. 1f, FIG. 2e). As VEGF is one of the main angiogenesis mediators, we have explored the hypothesis whether NMDAR activation is involved in angiogenesis. In the matrigel assay, MK-801 and the competitive NMDAR antagonist DAP-5 decrease total tube length formation and the number of nodes (FIG. 1g FIG. 2f). In a second in vitro angiogenesis assay based on hPMVECs and hPASMCs co-culture, MK-801 dose-dependently inhibits the formation of the endothelial tube network (FIG. 1h, FIG. 2g). We conclude that NMDAR is dysregulated in endothelial cells in PAH intimal and plexiform lesions and contributes to vascular remodeling. Moreover it participates to VEGF proliferation and angiogenesis.

(21) Discussion

(22) Using electron microscopy on human pulmonary tissues from PAH and control patient, we have observed a local concentration of NMDAR in synaptic-like contact between endothelial cells, especially in the plexiform lesion, a PAH-typical lesion characterized by disorganized and excessive angiogenesis in which increased VEGF signaling has been previously pointed out.sup.41. In cerebellar granule cells, VEGFR-2 physically interacts with NMDAR modulating its activity .sup.42. Here we have shown that NMDAR antagonists are able to dose-dependently inhibit VEGF-induced proliferation and angiogenesis. Intriguingly, expression of NMDAR-associated synaptic proteins neurologin and neurexin that trigger synapse formation in the CNS have already been described in vascular cells playing a role in angiogenesis.sup.56 and common variants in cerebellin 2, a partner of neurexin and expressed by pulmonary endothelial cells, increases the risk of PAH by approximately two-fold.sup.57.

REFERENCES

(23) Throughout this application, various references describe the state of the art to which this invention pertains. The disclosures of these references are hereby incorporated by reference into the present disclosure.

(24) 5. Traynelis, S. F. et al. Glutamate Receptor Ion Channels: Structure, Regulation, and Function. Pharmacol. Rev. 62, 405-496 (2010).

(25) 6. Petralia, R. S. Distribution of Extrasynaptic NMDA Receptors on Neurons. Sci. World J. 2012, e267120 (2012).

(26) 7. Dong, X., Wang, Y. & Qin, Z. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol. Sin. 30, 379-387 (2009).

(27) 8. Barkus, C. et al. Hippocampal NMDA receptors and anxiety: At the interface between cognition and emotion. Eur. J. Pharmacol. 626, 49-56 (2010).

(28) 9. Wesseling, H. et al. Integrative proteomic analysis of the NMDA NR1 knockdown mouse model reveals effects on central and peripheral pathways associated with schizophrenia and autism spectrum disorders. Mol. Autism 5, 38 (2014).

(29) 10. Paoletti, P., Bellone, C. & Zhou, Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat. Rev. Neurosci. 14, 383-400 (2013).

(30) 11. Parsons, M. P. & Raymond, L. A. Extrasynaptic NMDA Receptor Involvement in Central Nervous System Disorders. Neuron 82, 279-293 (2014).

(31) 12. Nedergaard, M., Takano, T. & Hansen, A. J. Beyond the role of glutamate as a neurotransmitter. Nat. Rev. Neurosci. 3, 748-755 (2002).

(32) 13. Genever, P. G. & Skerry, T. M. Glutamate signalling in bone: a therapeutic target for osteoporosis? Expert Opin. Ther. Targets 4, 207-218 (2000).

(33) 14. Bozic, M. & Valdivielso, J. M. The potential of targeting NMDA receptors outside the CNS. Expert Opin. Ther. Targets 19, 399-413 (2014).

(34) 15. Marquard, J. et al. Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment. Nat. Med. 21, 363-372 (2015).

(35) 16. Affaticati, P. et al. Sustained calcium signalling and caspase-3 activation involve NMDA receptors in thymocytes in contact with dendritic cells. Cell Death Differ. 18, 99-108 (2011).

(36) 17. Malomouzh, A. I., Nurullin, L. F., Arkhipova, S. S. & Nikolsky, E. E. NMDA receptors at the endplate of rat skeletal muscles: Precise postsynaptic localization. Muscle Nerve 44, 987-989 (2011).

(37) 18. Sharp, C. D. et al. Glutamate causes a loss in human cerebral endothelial barrier integrity through activation of NMDA receptor. Am. J. Physiol. Heart Circ. Physiol. 285, H2592-2598 (2003).

(38) 19. Sharp, C. D. et al. N-methyl-D-aspartate receptor activation in human cerebral endothelium promotes intracellular oxidant stress. Am. J. Physiol. Heart Circ. Physiol. 288, H1893-1899 (2005).

(39) 20. Reijerkerk, A. et al. The NR1 subunit of NMDA receptor regulates monocyte transmigration through the brain endothelial cell barrier. J. Neurochem. 113, 447-453 (2010).

(40) 21. Andrs, I. E. et al. The NMDA and AMPA/KA receptors are involved in glutamate-induced alterations of occludin expression and phosphorylation in brain endothelial cells. J. Cereb. Blood Flow Metab. 27, 1431-1443 (2007).

(41) 22. Chen, H. et al. Identification of a homocysteine receptor in the peripheral endothelium and its role in proliferation. J. Vasc. Surg. 41, 853-860 (2005).

(42) 23. Parfenova, H. Glutamate induces oxidative stress and apoptosis in cerebral vascular endothelial cells: contributions of HO-1 and HO-2 to cytoprotection. AJP Cell Physiol. 290, C1399-C1410 (2005).

(43) 24. Beard, R. S., Reynolds, J. J. & Bearden, S. E. Hyperhomocysteinemia increases permeability of the blood-brain barrier by NMDA receptor-dependent regulation of adherens and tight junctions. Blood 118, 2007-2014 (2011).

(44) 25. Doronzo, G. et al. Role of NMDA receptor in homocysteine-induced activation of mitogen-activated protein kinase and phosphatidyl inositol 3-kinase pathways in cultured human vascular smooth muscle cells. Thromb. Res. 125, e23-32 (2010).

(45) 26. Moriyama, Y. & Yamamoto, A. Glutamatergic Chemical Transmission: Look! Here, There, and Anywhere. J. Biochem. (Tokyo) 135, 155-163 (2004).

(46) 27. Li, L. & Hanahan, D. Hijacking the neuronal NMDAR signaling circuit to promote tumor growth and invasion. Cell 153, 86-100 (2013).

(47) 28. Stepulak, A. et al. NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth. Proc. Natl. Acad. Sci. U.S.A. 102, 15605-15610 (2005).

(48) 29. Rzeski, W., Turski, L. & Ikonomidou, C. Glutamate antagonists limit tumor growth. Proc. Natl. Acad. Sci. U.S.A. 98, 6372-6377 (2001).

(49) 30. Guignabert, C. et al. Pathogenesis of pulmonary arterial hypertension: lessons from cancer. Eur. Respir. Rev. 22, 543-551 (2013).

(50) 37. Perros, F. et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 178, 81-88 (2008).

(51) 38. Lei, S. et al. Platelet-derived growth factor receptor-induced feed-forward inhibition of excitatory transmission between hippocampal pyramidal neurons. J. Biol. Chem. 274, 30617-30623 (1999).

(52) 39. Beazely, M. A. et al. Platelet-derived Growth Factor Selectively Inhibits NR2B-containing N-Methyl-D-aspartate Receptors in CA1 Hippocampal Neurons. J. Biol. Chem. 284, 8054-8063 (2009).

(53) 41. Tuder, R. M. et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J. Pathol. 195, 367-374 (2001).

(54) 42. Meissirel, C. et al. VEGF modulates NMDA receptors activity in cerebellar granule cells through Src-family kinases before synapse formation. Proc. Natl. Acad. Sci. U.S.A. 108, 13782-13787 (2011).

(55) 56. Bottos, A. et al. The synaptic proteins neurexins and neuroligins are widely expressed in the vascular system and contribute to its functions. Proc. Natl. Acad. Sci. 106, 20782-20787 (2009).